TCM Formula
Phase 3Small molecule
TCM Formula is one of 68 small molecule programs targeting Fatigue. It is currently in Phase 3.
3
Indications
3
Total Trials
0
Active Trials
67
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
200 competitors in Eye Disease
#DrugCompanyPhaseTrials
1Alphagan
AbbViePhase 3
Chantix
PfizerPhase 3
CF101
CCan-Fite BioPharma
Phase 3
Refresh Plus
AbbViePhase 3
TCM Formula
PPeking University Cancer Hospital & Institute
Phase 3
Cenegermin
DDompé Farmaceutici S.p.A
Phase 3
Csa
ZZhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.
Phase 3
Diquafosol Tetrasodium
Merck & Co.Phase 3
REFRESH LIQUIGEL
AbbViePhase 3
Refresh Optive
AbbViePhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Eye Disease1 trial
Effect of Traditional Chinese Medicine on Basic Tear Secretion and Tear Cytokines in Patients With Dry Eye Disease
Unknown status·—·Phase 2·NCT04785261·60 enrolled
Adverse Effect1 trial
Prophylactic TCM for Mitigation of EGFR-TKI Related Dermatological Adverse Effect
Completed·—·Phase 3·NCT05204758·30 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TCM Formula. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details